Repository logo
 
Publication

Anthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ breast cancer: real-world evidence

2023-07-21Journal article Open access
Simple item page
dc.contributor.authorPinho, Inês Soares de
dc.contributor.authorLuz, Paulo
dc.contributor.authorAlves, Lucy
dc.contributor.authorBrás, Raquel Lopes
dc.contributor.authorPatel, Vanessa
dc.contributor.authorMartins, Miguel Esperança
dc.contributor.authorGonçalves, Lisa
dc.contributor.authorFreitas, Ritas
dc.contributor.authorSimão, Diana
dc.contributor.authorRoldán Galnares, Maria
dc.contributor.authorFernandes, Isabel
dc.contributor.authorCriado, Silvia Artacho
dc.contributor.authorGamez Casado, Salvador
dc.contributor.authorBaena Cañada, Jose
dc.contributor.authorVega, Isabel M. Saffie
dc.contributor.authorCosta, João G.
dc.contributor.authorFernandes, Ana S.
dc.contributor.authorSousa, Rita Teixeira de
dc.contributor.authorCosta, Luís
dc.date.accessioned2025-03-24T10:23:32Z
dc.date.available2025-03-24T10:23:32Z
dc.date.issued2023-07-21
dc.description.abstractDeescalation strategies omitting anthracyclines (AC) have been explored in early human epidermal growth factor receptor 2-positive breast cancer (HER2+ EBC), showing similar efcacy regarding pathological complete response (pCR) and long-term outcomes as AC-containing regimens. The standard treatment for this tumor subtype is based on chemotherapy and dual HER2 blockade with trastuzumab and pertuzumab, with AC-containing regimens remaining a frequent option for these patients, even in non-high-risk cases. The primary aim of this study was to assess and compare the efectiveness of neoadjuvant regimens with and without AC used in the treatment of HER2+ EBC in the clinical practice according to the pCR achieved with each.eng
dc.description.sponsorshipUIDP/04567/2020
dc.identifier.doi10.1007/s40261-023-01291-6
dc.identifier.eissn1179-1918
dc.identifier.issn1173-2563
dc.identifier.urihttp://hdl.handle.net/10400.1/26945
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSpringer Scienc
dc.relationResearch Center for Biosciences & Health Technologies
dc.relationUIDP/04567/2020
dc.relation.hasversionhttps://link.springer.com/article/10.1007/s40261-023-01291-6
dc.relation.ispartofClinical Drug Investigation
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectEarly breast-cancer
dc.subjectPertuzumab plus trastuzumab
dc.subjectSafety
dc.subjectChemotherapy
dc.subjectPaclitaxel
dc.subjectEfficacy
dc.subjectWomen
dc.subjectRisk
dc.titleAnthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ breast cancer: real-world evidenceeng
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleResearch Center for Biosciences & Health Technologies
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04567%2F2020/PT
oaire.citation.endPage698
oaire.citation.issue9
oaire.citation.startPage691
oaire.citation.titleClinical Drug Investigation
oaire.citation.volume43
oaire.fundingStream6817 - DCRRNI ID
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
relation.isProjectOfPublication61bf546c-d2ee-49b0-adf1-bf66f15e9deb
relation.isProjectOfPublication.latestForDiscovery61bf546c-d2ee-49b0-adf1-bf66f15e9deb

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+Breast Cancer.pdf
Size:
841.06 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ULS_10.1-MED-Artigos